Zynex, Inc. (NASDAQ:ZYXI - Get Free Report) CFO Daniel J. Moorhead sold 10,000 shares of the company's stock in a transaction on Friday, November 1st. The shares were sold at an average price of $8.59, for a total transaction of $85,900.00. Following the transaction, the chief financial officer now owns 44,878 shares of the company's stock, valued at approximately $385,502.02. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Zynex Price Performance
NASDAQ:ZYXI opened at $8.00 on Tuesday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94. The company has a 50-day moving average of $8.10 and a 200-day moving average of $9.02. Zynex, Inc. has a 52 week low of $7.15 and a 52 week high of $13.77. The company has a market capitalization of $254.77 million, a price-to-earnings ratio of 53.33 and a beta of 0.53.
Zynex (NASDAQ:ZYXI - Get Free Report) last announced its quarterly earnings results on Thursday, October 24th. The company reported $0.07 EPS for the quarter, topping analysts' consensus estimates of $0.06 by $0.01. Zynex had a net margin of 2.49% and a return on equity of 13.05%. The firm had revenue of $49.97 million during the quarter, compared to analysts' expectations of $50.83 million. During the same quarter last year, the company earned $0.10 earnings per share. The company's revenue for the quarter was up .1% compared to the same quarter last year. As a group, equities research analysts anticipate that Zynex, Inc. will post 0.2 earnings per share for the current fiscal year.
Institutional Trading of Zynex
Financial Prophecy
From Porter & Company | Ad
The Magnificent 7 could be in for a world of pain…
And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock.
The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on.
It’s called The Final Frontier.
Including the name of the #1 company to buy.
A number of large investors have recently bought and sold shares of ZYXI. Vanguard Group Inc. boosted its stake in shares of Zynex by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 1,187,089 shares of the company's stock valued at $14,684,000 after purchasing an additional 6,097 shares in the last quarter. Millennium Management LLC boosted its position in Zynex by 66.5% in the second quarter. Millennium Management LLC now owns 297,082 shares of the company's stock valued at $2,769,000 after buying an additional 118,615 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Zynex by 1.6% during the second quarter. Bank of New York Mellon Corp now owns 192,832 shares of the company's stock worth $1,797,000 after buying an additional 2,954 shares during the last quarter. Renaissance Technologies LLC grew its stake in Zynex by 68.7% during the second quarter. Renaissance Technologies LLC now owns 189,762 shares of the company's stock worth $1,769,000 after buying an additional 77,300 shares during the last quarter. Finally, Janney Montgomery Scott LLC increased its holdings in shares of Zynex by 22.3% during the third quarter. Janney Montgomery Scott LLC now owns 144,439 shares of the company's stock worth $1,179,000 after buying an additional 26,368 shares in the last quarter. 29.68% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on ZYXI shares. Royal Bank of Canada cut their price objective on shares of Zynex from $12.00 to $11.00 and set an "outperform" rating for the company in a research report on Tuesday, October 8th. HC Wainwright raised their price objective on Zynex from $16.00 to $17.00 and gave the stock a "buy" rating in a research report on Friday, October 25th.
Check Out Our Latest Stock Analysis on ZYXI
About Zynex
(
Get Free Report)
Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
